bims-hummad Biomed News
on Humanised mouse models of autoimmune disorders
Issue of 2026–11–15
four papers selected by
Maksym V. Kopanitsa, Charles River Laboratories



  1. Diabetes. 2026 Nov 10. pii: db260373. [Epub ahead of print]
      Immune-mediated rejection remains a major barrier to long-term success of islet/stem cell-derived islet transplantation for type 1 diabetes. We evaluated whether cotransplantation of human islets with human α-1 antitrypsin-overexpressing mesenchymal stromal/stem cells (AAT-MSCs) improves islet graft survival by modulating human immune responses in a humanized diabetic mouse model. Humanized NOD/SCID/IL2Rγ-/- (NSG) mice were generated by irradiation and transfer of human CD34+ hematopoietic stem/progenitor cells, resulting in stable T- and B-cell reconstitution. Diabetes was induced by multiple doses of low-dose streptozotocin (STZ), after which mice received intrahepatic transplants of human islets alone or together with AAT-MSCs and were monitored for 100 days. Cotransplantation with AAT-MSCs markedly improved glycemic control, prolonged graft survival, and reduced the risk of rejection. These beneficial effects were associated with lower serum IgM levels, which inversely correlated with graft rejection, and with expansion of regulatory B cells (Bregs), followed by durable suppression of T helper 1, T helper 17, and cytotoxic T cell responses. Cotransplant grafts showed improved insulin preservation and enrichment of interleukin (IL) 10+ cells within islets. In vitro, AAT-MSCs promoted Breg differentiation, shifted cytokine production toward IL-10 over IL-6, and attenuated activated B cell-mediated cytotoxicity against human islets. Collectively, these findings demonstrate that AAT-MSC cotransplantation promotes immune tolerance and human islet graft function, supporting its translational potential to reduce reliance on systemic immunosuppression in the clinic.
    ARTICLE HIGHLIGHTS: Immune-mediated rejection limits the long-term success of islet and stem cell-derived islet transplantation in type 1 diabetes, and strategies that protect the graft without systemic immunosuppression are needed. We asked whether cotransplanting human islets with α-1 antitrypsin-overexpressing mesenchymal stromal/stem cells (AAT-MSCs) improves graft outcomes in humanized mice, and how human immune responses are affected. AAT-MSC cotransplantation improved glycemic control, prolonged graft survival, and shifted immune responses toward a more regulatory, less inflammatory profile. These findings support further development of AAT-MSCs as an adjunct to reduce reliance on systemic immunosuppression in islet transplantation.
    DOI:  https://doi.org/10.2337/db26-0373
  2. Front Immunol. 2026 ;17 1967450
       Background: Peripheral blood mononuclear cell (PBMC)-humanized mouse models are critical tools for preclinical evaluation of cancer immunotherapies, yet current models offer limited recapitulation of human immune diversity, particularly myeloid and natural killer (NK) cells. To address this limitation, we generated a novel immunocompromised mouse strain NSG-SGM3-IL15-DKO (S15-DKO) combining the NSG-MHC I/II double-knockout (DKO), which delays xenogeneic graft-versus-host disease, with the NSG-SGM3-IL15 human cytokine-expressing strain. Here, we evaluated PBMC engraftment and established a humanized immune-oncology model to test bispecific T cell engager (BiTE) efficacy and cytokine release in S15-DKO mice compared to DKO mice.
    Methods: S15-DKO and DKO mice were engrafted with 1x107 human PBMCs from various healthy donors, with or without prior exposure to Raji lymphoma cells or irradiation. Retro-orbital (RO) blood (and spleen) was collected to assess human immune cells engraftment by flow cytometry. Irradiated, Raji-bearing S15-DKO and DKO mice were treated with PBS or anti-CD3xCD19 BiTE. Bioluminescence imaging was performed to measure tumor burden, and plasma was collected to measure cytokine levels.
    Results: S15-DKO mice engrafted with PBMCs from multiple donors supported significantly higher levels of human CD45+ cells, CD4+ and CD8+ T cells, and NK cells compared to DKO mice without the need for irradiation, with body weight changes and survival comparable to DKO controls. B cells, dendritic cells, and macrophages also showed significantly improved engraftment in S15-DKO mice compared to DKO mice with certain PBMC donors. Engraftment of PBMCs in S15-DKO mice bearing Raji lymphoma cells was also higher compared to DKO mice, with significantly elevated numbers of NK cells and dendritic cells in addition to T cells. Preconditioning the S15-DKO mice with irradiation prior to PBMC engraftment further enhanced immune cell reconstitution, accelerating engraftment kinetics and increasing absolute cell counts across multiple immune subsets. In a therapeutic model, irradiated S15-DKO mice bearing Raji-luc cells demonstrated superior tumor reduction and significantly higher levels of cytokine release compared to DKO mice following anti-CD3xCD19 BiTE treatment.
    Discussion: These findings establish PBMC-humanized S15-DKO mice as a novel preclinical platform for evaluating efficacy and cytokine release of immunotherapies that require diverse populations of human immune cells.
    Keywords:  NSG-SGM3-IL15-DKO (S15-DKO); bispecific T cell engagers; humanized mouse model; immunotherapy; myeloid cells; natural killer cells; peripheral blood mononuclear cell (PBMC)
    DOI:  https://doi.org/10.3389/fimmu.2026.1967450
  3. Sci Adv. 2026 Nov 13. 12(46): eaej2663
      PRGN-3008 is a CD19 CAR T cell designed to overcome key limitations in ex vivo and in vivo CAR T manufacturing, cost, safety, and therapeutic durability. Featuring decentralized overnight manufacturing without ex vivo expansion, PRGN-3008 is engineered using a single nonviral transposon to encode CD19 CAR, membrane-bound interleukin-15 (mbIL-15) for improved persistence, PD-1-targeting microRNAs to prevent exhaustion, and an inducible safety switch for controlled in vivo elimination. Safety studies showed low vector copy numbers, favorable integration profile, and efficient CAR T ablation upon safety-switch activation. The combined mbIL-15 expression and PD-1 down-regulation preserved PRGN-3008 polyfunctionality and sustained cytotoxicity across repeated tumor challenges, outperforming nonarmored or singly modified CAR T cells. In xenograft models, overnight-manufactured PRGN-3008 without ex vivo expansion and activation achieved durable tumor clearance, prolonged tumor-free survival, robust antigen dependent expansion, and enrichment of memory T cell phenotypes linked to clinical durability. Notably, PRGN-3008 generated from heavily pretreated patients with systemic lupus erythematosus or lupus nephritis, maintained effector function, resisted terminal differentiation under chronic antigen exposure, and effectively depleted autoreactive B cells in a humanized mouse model. Transcriptomic analysis revealed that the combination of mbIL-15 expression and PD-1 down-regulation enhances the expression of genes associated with bioenergetic pathways, including oxidative phosphorylation, mitochondrial biogenesis, glycolysis, and glutamine utilization, thereby supporting resistance to exhaustion and sustained effector function. Collectively, these data support PRGN-3008 as a clinically translatable, scalable, and controllable CAR T with the potential to expand access to cell therapy across oncology and autoimmune indications.
    DOI:  https://doi.org/10.1126/sciadv.aej2663
  4. Int J Mol Sci. 2026 Oct 28. pii: 9658. [Epub ahead of print]27(21):
      Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder in which enhanced platelet destruction and impaired platelet production coexist, and a substantial proportion of patients remain refractory to available therapies. Here, we evaluated 2B9-Fc, a thrombopoietin (TPO) mimetic peptide engineered from a cyclic peptide with high affinity for both human and mouse c-MPL, in passive (anti-CD41 monoclonal antibody R300) and active (guinea pig anti-mouse platelet serum, GP-APS) immunization male C57BL/6J and humanized c-MPL receptor transgenic mouse models of ITP. 2B9-Fc (500 μg/kg, subcutaneously) significantly elevated peripheral platelet counts in both models (p < 0.01), without affecting WBC, RBC, or hemoglobin, and alleviated skin purpura and bleeding scores in the active model. In addition, 2B9-Fc treatment was associated with a reduced splenic M1/M2 macrophage ratio, increased regulatory T cells (Tregs), downregulated IL-6 and iNOS while upregulating TGF-β1 and Foxp3, and suppressed STAT1 phosphorylation. In humanized c-MPL receptor transgenic (MT) mice, 2B9-Fc promoted CD41+ megakaryocyte generation in vitro and sustained platelet recovery in vivo through day 14. These results indicate that 2B9-Fc ameliorates ITP and is associated with promotion of megakaryocyte maturation and restoration of immune tolerance, likely involving inhibition of STAT1-mediated M1 polarization and Treg expansion, supporting its potential for clinical translation.
    Keywords:  c-MPL receptor; immune thrombocytopenia; macrophage polarization; regulatory T cells; thrombopoietin receptor agonist
    DOI:  https://doi.org/10.3390/ijms27219658